Dr Ian Woodcock
Dr Ian Woodcock
Dr Ian Woodcock is a paediatric neurologist at The Royal Children’s Hospital (RCH) in Melbourne and a Research Fellow at the Murdoch Children’s Research Institute. Dr Woodcock completed his FRACP fellowship training in 2018 and is currently completing a PhD at the University of Melbourne, studying novel therapies for neurological rare diseases.
Dr Woodcock has been involved in 20 industry sponsored clinical trials since 2017; 14 as a sub-investigator and six as a principal investigator. Dr Woodcock is the principal investigator in four current gene therapy clinical trials, three in DMD and one in Spinal Muscular Atrophy (SMA).
Dr Woodcock was the principal investigator in an investigator-led trial of creatine monohydrate in paediatric patients with FSHD (NCT02948244). This was the first international randomized clinical trial in paediatric FSHD and, within Australia, the first clinical trial involving patients of any age with FSHD. Through his research in FSHD he has collated the largest repository of muscle MRI scans in paediatric patients with FSHD, part of ongoing projects to assess and validate MRI as a biomarker in paediatric FSHD. This resulted in the first published data investigating the use of MRI as an outcome measure and biomarker in paediatric FSHD. He is co-leading a natural history study in paediatric FSHD, specifically looking at assessing outcome measures to improve clinical trial readiness. This study will serve as pilot data for a proposed larger, international paediatric natural history study planned to start in 2024.
Dr Woodcock has been sought out as an Associate Investigator on multiple laboratory-based grant applications looking at induced pluripotent stems in FSHD, developing a humanised mouse model for FSHD and looking to perform high-throughput drug screening using a DUX4-inducible 2D myotube model.
Dr Woodcock is a co-author and team member in the pivotal New Eng J. Med. publication of the ENDEAR study, which led to a paradigm shift in treatment for SMA type 1, resulting in the first FDA-approved disease modifying treatment for patients with SMA. Dr Woodcock is involved in instigating translational change to prepare the Melbourne Children’s Campus to be an approved gene therapy centre and has now dosed more than ten individuals with gene therapy in SMA, DMD and recently Dravet’s Syndrome.
Publications: In the last 5 years, Dr Woodcock has authored 14 peer reviewed publications (citations: >910; average FWCI: 7.53),
Research support: Dr Woodcock has been successful in multiple competitive grant funding, mainly for ongoing research projects in paediatric FSHD, totalling more than AUD$530,000.
Dr Woodcock was selected by the RCH and MCRI executives to participate in the first working group on our campus to establish The Melbourne Children’s Campus as a national centre for gene and other advanced and novel therapies. This work culminated in patients with SMA receiving TGA-approved gene therapy in July 2021.
Dr Woodcock chaired the organizing committees of the Australasian Neuromuscular Network (ANN) Congresses in 2021, 2022 and 2023. He is a member of the British Paediatric Neurology Association, World Muscle Society and American Academy of Neurologists. He was elected as the inaugural President of the ANN and oversaw the transition of the ANN into an incorporated society.
Dr. Woodcock has constructed the AUSNMD website, which links the NMD community, health professionals and industry to provide information on clinical trials, best practice management and emerging therapies. Dr. Woodcock has close links with FSHD Global Research Foundation and recently assisted in their launch of the Parliamentary Friends of FSHD program. He is regularly an invited member of industry advisory boards including Biogen, Roche, Novartis and Pfizer.
Dr Woodcock has been involved in 20 industry sponsored clinical trials since 2017; 14 as a sub-investigator and six as a principal investigator. Dr Woodcock is the principal investigator in four current gene therapy clinical trials, three in DMD and one in Spinal Muscular Atrophy (SMA).
Dr Woodcock was the principal investigator in an investigator-led trial of creatine monohydrate in paediatric patients with FSHD (NCT02948244). This was the first international randomized clinical trial in paediatric FSHD and, within Australia, the first clinical trial involving patients of any age with FSHD. Through his research in FSHD he has collated the largest repository of muscle MRI scans in paediatric patients with FSHD, part of ongoing projects to assess and validate MRI as a biomarker in paediatric FSHD. This resulted in the first published data investigating the use of MRI as an outcome measure and biomarker in paediatric FSHD. He is co-leading a natural history study in paediatric FSHD, specifically looking at assessing outcome measures to improve clinical trial readiness. This study will serve as pilot data for a proposed larger, international paediatric natural history study planned to start in 2024.
Dr Woodcock has been sought out as an Associate Investigator on multiple laboratory-based grant applications looking at induced pluripotent stems in FSHD, developing a humanised mouse model for FSHD and looking to perform high-throughput drug screening using a DUX4-inducible 2D myotube model.
Dr Woodcock is a co-author and team member in the pivotal New Eng J. Med. publication of the ENDEAR study, which led to a paradigm shift in treatment for SMA type 1, resulting in the first FDA-approved disease modifying treatment for patients with SMA. Dr Woodcock is involved in instigating translational change to prepare the Melbourne Children’s Campus to be an approved gene therapy centre and has now dosed more than ten individuals with gene therapy in SMA, DMD and recently Dravet’s Syndrome.
Publications: In the last 5 years, Dr Woodcock has authored 14 peer reviewed publications (citations: >910; average FWCI: 7.53),
Research support: Dr Woodcock has been successful in multiple competitive grant funding, mainly for ongoing research projects in paediatric FSHD, totalling more than AUD$530,000.
Dr Woodcock was selected by the RCH and MCRI executives to participate in the first working group on our campus to establish The Melbourne Children’s Campus as a national centre for gene and other advanced and novel therapies. This work culminated in patients with SMA receiving TGA-approved gene therapy in July 2021.
Dr Woodcock chaired the organizing committees of the Australasian Neuromuscular Network (ANN) Congresses in 2021, 2022 and 2023. He is a member of the British Paediatric Neurology Association, World Muscle Society and American Academy of Neurologists. He was elected as the inaugural President of the ANN and oversaw the transition of the ANN into an incorporated society.
Dr. Woodcock has constructed the AUSNMD website, which links the NMD community, health professionals and industry to provide information on clinical trials, best practice management and emerging therapies. Dr. Woodcock has close links with FSHD Global Research Foundation and recently assisted in their launch of the Parliamentary Friends of FSHD program. He is regularly an invited member of industry advisory boards including Biogen, Roche, Novartis and Pfizer.
Dr Ian Woodcock is a paediatric neurologist at The Royal Children’s Hospital (RCH) in Melbourne and a Research Fellow at the Murdoch Children’s Research Institute. Dr Woodcock completed his FRACP fellowship training in 2018 and is currently...
Dr Ian Woodcock is a paediatric neurologist at The Royal Children’s Hospital (RCH) in Melbourne and a Research Fellow at the Murdoch Children’s Research Institute. Dr Woodcock completed his FRACP fellowship training in 2018 and is currently completing a PhD at the University of Melbourne, studying novel therapies for neurological rare diseases.
Dr Woodcock has been involved in 20 industry sponsored clinical trials since 2017; 14 as a sub-investigator and six as a principal investigator. Dr Woodcock is the principal investigator in four current gene therapy clinical trials, three in DMD and one in Spinal Muscular Atrophy (SMA).
Dr Woodcock was the principal investigator in an investigator-led trial of creatine monohydrate in paediatric patients with FSHD (NCT02948244). This was the first international randomized clinical trial in paediatric FSHD and, within Australia, the first clinical trial involving patients of any age with FSHD. Through his research in FSHD he has collated the largest repository of muscle MRI scans in paediatric patients with FSHD, part of ongoing projects to assess and validate MRI as a biomarker in paediatric FSHD. This resulted in the first published data investigating the use of MRI as an outcome measure and biomarker in paediatric FSHD. He is co-leading a natural history study in paediatric FSHD, specifically looking at assessing outcome measures to improve clinical trial readiness. This study will serve as pilot data for a proposed larger, international paediatric natural history study planned to start in 2024.
Dr Woodcock has been sought out as an Associate Investigator on multiple laboratory-based grant applications looking at induced pluripotent stems in FSHD, developing a humanised mouse model for FSHD and looking to perform high-throughput drug screening using a DUX4-inducible 2D myotube model.
Dr Woodcock is a co-author and team member in the pivotal New Eng J. Med. publication of the ENDEAR study, which led to a paradigm shift in treatment for SMA type 1, resulting in the first FDA-approved disease modifying treatment for patients with SMA. Dr Woodcock is involved in instigating translational change to prepare the Melbourne Children’s Campus to be an approved gene therapy centre and has now dosed more than ten individuals with gene therapy in SMA, DMD and recently Dravet’s Syndrome.
Publications: In the last 5 years, Dr Woodcock has authored 14 peer reviewed publications (citations: >910; average FWCI: 7.53),
Research support: Dr Woodcock has been successful in multiple competitive grant funding, mainly for ongoing research projects in paediatric FSHD, totalling more than AUD$530,000.
Dr Woodcock was selected by the RCH and MCRI executives to participate in the first working group on our campus to establish The Melbourne Children’s Campus as a national centre for gene and other advanced and novel therapies. This work culminated in patients with SMA receiving TGA-approved gene therapy in July 2021.
Dr Woodcock chaired the organizing committees of the Australasian Neuromuscular Network (ANN) Congresses in 2021, 2022 and 2023. He is a member of the British Paediatric Neurology Association, World Muscle Society and American Academy of Neurologists. He was elected as the inaugural President of the ANN and oversaw the transition of the ANN into an incorporated society.
Dr. Woodcock has constructed the AUSNMD website, which links the NMD community, health professionals and industry to provide information on clinical trials, best practice management and emerging therapies. Dr. Woodcock has close links with FSHD Global Research Foundation and recently assisted in their launch of the Parliamentary Friends of FSHD program. He is regularly an invited member of industry advisory boards including Biogen, Roche, Novartis and Pfizer.
Dr Woodcock has been involved in 20 industry sponsored clinical trials since 2017; 14 as a sub-investigator and six as a principal investigator. Dr Woodcock is the principal investigator in four current gene therapy clinical trials, three in DMD and one in Spinal Muscular Atrophy (SMA).
Dr Woodcock was the principal investigator in an investigator-led trial of creatine monohydrate in paediatric patients with FSHD (NCT02948244). This was the first international randomized clinical trial in paediatric FSHD and, within Australia, the first clinical trial involving patients of any age with FSHD. Through his research in FSHD he has collated the largest repository of muscle MRI scans in paediatric patients with FSHD, part of ongoing projects to assess and validate MRI as a biomarker in paediatric FSHD. This resulted in the first published data investigating the use of MRI as an outcome measure and biomarker in paediatric FSHD. He is co-leading a natural history study in paediatric FSHD, specifically looking at assessing outcome measures to improve clinical trial readiness. This study will serve as pilot data for a proposed larger, international paediatric natural history study planned to start in 2024.
Dr Woodcock has been sought out as an Associate Investigator on multiple laboratory-based grant applications looking at induced pluripotent stems in FSHD, developing a humanised mouse model for FSHD and looking to perform high-throughput drug screening using a DUX4-inducible 2D myotube model.
Dr Woodcock is a co-author and team member in the pivotal New Eng J. Med. publication of the ENDEAR study, which led to a paradigm shift in treatment for SMA type 1, resulting in the first FDA-approved disease modifying treatment for patients with SMA. Dr Woodcock is involved in instigating translational change to prepare the Melbourne Children’s Campus to be an approved gene therapy centre and has now dosed more than ten individuals with gene therapy in SMA, DMD and recently Dravet’s Syndrome.
Publications: In the last 5 years, Dr Woodcock has authored 14 peer reviewed publications (citations: >910; average FWCI: 7.53),
Research support: Dr Woodcock has been successful in multiple competitive grant funding, mainly for ongoing research projects in paediatric FSHD, totalling more than AUD$530,000.
Dr Woodcock was selected by the RCH and MCRI executives to participate in the first working group on our campus to establish The Melbourne Children’s Campus as a national centre for gene and other advanced and novel therapies. This work culminated in patients with SMA receiving TGA-approved gene therapy in July 2021.
Dr Woodcock chaired the organizing committees of the Australasian Neuromuscular Network (ANN) Congresses in 2021, 2022 and 2023. He is a member of the British Paediatric Neurology Association, World Muscle Society and American Academy of Neurologists. He was elected as the inaugural President of the ANN and oversaw the transition of the ANN into an incorporated society.
Dr. Woodcock has constructed the AUSNMD website, which links the NMD community, health professionals and industry to provide information on clinical trials, best practice management and emerging therapies. Dr. Woodcock has close links with FSHD Global Research Foundation and recently assisted in their launch of the Parliamentary Friends of FSHD program. He is regularly an invited member of industry advisory boards including Biogen, Roche, Novartis and Pfizer.
Top Publications
- Dijkstra, JN, Erasmus, CE, Laurian, P, Roets, A, Dodd, M, Irving, K, Moreno, CAM, Woodcock, IR, Voermans, NC, Willis, T, et al. Framing childhood-onset facioscapulohumeral dystrophy: from first symptoms to future trials.. Neuromuscul Disord 62: 106385 2026 view publication
- Kwon, JM, Munell, F, Le Goff, L, Yuge, K, Kato, T, Cances, C, De Waele, L, Woodcock, IR, Mercuri, EM, Proud, CM, et al. Intrathecal onasemnogene abeparvovec for treatment-experienced patients with spinal muscular atrophy: a phase 3b, open-label trial.. Nat Med 32(2) : 488 -493 2026 view publication
- Kwon, JM, Munell, F, Le Goff, L, Yuge, K, Kato, T, Cances, C, De Waele, L, Woodcock, IR, Mercuri, EM, Proud, CM, et al. Author Correction: Intrathecal onasemnogene abeparvovec for treatment-experienced patients with spinal muscular atrophy: a phase 3b, open-label trial.. Nat Med 32(2) : 763 2026 view publication
- Grobler, A, Woodcock, I. Statistical analysis plan. 2026 view publication
- Woodcock, I, Tachas, G, Desem, N, Houweling, P, Yiu, E, Kean, M, Emmanuel, J, Kennedy, R, Carroll, K, de Valle, K, et al. A Phase 2 open-label study to determine the safety and efficacy of weekly dosing of ATL1102 in patients with non-ambulatory Duchenne muscular dystrophy. 2026 view publication
Page 1 of 8
Career information
Share //
